NEWS
The Chiesi Group chooses Norameda
Leber’s Hereditary Optic Neuropathy (LHON) – a devastating diagnosis. It is a heritable genetic disease causing profound vision loss and blindness. Unfortunately, there is no cure. And ways of treatment are limited. The disease presents predominantly in young,...
Twenty-one years and counting. Meet Head of Norameda – Audrius Leiva
Audrius Leiva, General Manager of Norameda, remembers the beginning of his career at the encounter of two decades with a smile. It was a thrilling and challenging time for a young professional. Despite family tradition, medical graduate had embraced a different path....
Special Care Medicine Department: “Every single life matter”
“Sales are important but no more than people we work for or with. And I am confident, this is the main factor of our success”, – says Sandra Ivanauskiene, founder and leader of the Norameda Special Care Medicine Department since 2017. This unique Norameda’s division...
Pharma market vs COVID: some numbers and future prognosis
The biggest challenge for the European health system – massive backlogs, generated by the pandemic. There is uncertainty about recovery rates and the time required to clear them. For example, the EU backlog is estimated at ca. 1 bn diagnosis visits.